《大行報告》瑞銀下調百濟神州(BGNE.US)目標價至310.8美元 評級「買入」
瑞銀發表研報指,百濟神州(06160.HK)(BGNE.US)旗下產品替雷利珠單抗「百澤安」(TEVIMBRA)近日於歐美兩地均取得進展,新藥上市申請獲美國FDA受理外,歐盟委員會亦已批准該產品用於治療ESCC成人患者。
該行表示,百濟神州已與諾華公司簽訂相互終止和解除協議,重新取得開發、生產和商業化替雷利珠單抗的全部全球權利,認為該藥近日獲得歐盟批准,標誌著公司全球化進程再邁進一步,重新取得全球權益將有助於獨立研發和商業化。
瑞銀繼續列百濟神州為中國生物科技行業的首選股份,維持「買入」評級。由於產品特許授權及里程碑費用減少,以及並百澤安海外銷售額預期下降,該行將百濟神州2023至2025年收入預測下調7.3%、13.2%及20.7%,美股目標價從318.2美元降至310.8美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.